曲美替尼对一名 BRAF 基因突变的转移性尿路上皮癌患者的疗效

Q4 Medicine IJU Case Reports Pub Date : 2024-07-10 DOI:10.1002/iju5.12759

Hiroyuki Karasawa, Yota Yasumizu, Takeo Kosaka, Tatsunori Shimoi, Mototsugu Oya

{"title":"曲美替尼对一名 BRAF 基因突变的转移性尿路上皮癌患者的疗效","authors":"Hiroyuki Karasawa, Yota Yasumizu, Takeo Kosaka, Tatsunori Shimoi, Mototsugu Oya","doi":"10.1002/iju5.12759","DOIUrl":null,"url":null,"abstract":"<div>\n \n <section>\n \n <h3> Introduction</h3>\n \n <p>BRAF mutations in bladder cancer are rare. MEK inhibitors have excellent clinical benefits in the treatment of melanoma.</p>\n </section>\n \n <section>\n \n <h3> Case presentation</h3>\n \n <p>A 60-year-old male was diagnosed with muscle-invasive bladder cancer and underwent total cystectomy and ileal conduit diversion. Despite 4 cycles of gemcitabine and cisplatin chemotherapy and 3 courses of pembrolizumab, the left obturator lymph node enlarged. Cancer multi-gene panel testing confirmed the BRAF G469A mutation and trametinib was recommended. Three months after the initiation of trametinib (2 mg, qd), the left obturator lymph node shrank by more than 50%. The disease has remained stable for more than 18 months.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>The present case indicates the potential of trametinib to treat mBUC patients with the BRAF G469A mutation in this setting.</p>\n </section>\n </div>","PeriodicalId":52909,"journal":{"name":"IJU Case Reports","volume":"7 5","pages":"375-378"},"PeriodicalIF":0.0000,"publicationDate":"2024-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/iju5.12759","citationCount":"0","resultStr":"{\"title\":\"Efficacy of trametinib in a metastatic urothelial carcinoma patient with a BRAF mutation\",\"authors\":\"Hiroyuki Karasawa, Yota Yasumizu, Takeo Kosaka, Tatsunori Shimoi, Mototsugu Oya\",\"doi\":\"10.1002/iju5.12759\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n <section>\\n \\n <h3> Introduction</h3>\\n \\n <p>BRAF mutations in bladder cancer are rare. MEK inhibitors have excellent clinical benefits in the treatment of melanoma.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Case presentation</h3>\\n \\n <p>A 60-year-old male was diagnosed with muscle-invasive bladder cancer and underwent total cystectomy and ileal conduit diversion. Despite 4 cycles of gemcitabine and cisplatin chemotherapy and 3 courses of pembrolizumab, the left obturator lymph node enlarged. Cancer multi-gene panel testing confirmed the BRAF G469A mutation and trametinib was recommended. Three months after the initiation of trametinib (2 mg, qd), the left obturator lymph node shrank by more than 50%. The disease has remained stable for more than 18 months.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>The present case indicates the potential of trametinib to treat mBUC patients with the BRAF G469A mutation in this setting.</p>\\n </section>\\n </div>\",\"PeriodicalId\":52909,\"journal\":{\"name\":\"IJU Case Reports\",\"volume\":\"7 5\",\"pages\":\"375-378\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-07-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/iju5.12759\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"IJU Case Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/iju5.12759\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"IJU Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/iju5.12759","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

膀胱癌中的 BRAF 基因突变非常罕见。MEK抑制剂在治疗黑色素瘤方面有很好的临床疗效。一名60岁的男性被诊断为肌肉浸润性膀胱癌，接受了全膀胱切除术和回肠导流术。尽管接受了 4 个周期的吉西他滨和顺铂化疗以及 3 个疗程的 Pembrolizumab 治疗，但左侧钝器淋巴结肿大。癌症多基因面板检测证实了 BRAF G469A 突变，建议使用曲美替尼。开始服用曲美替尼（2 毫克，每天一次）三个月后，左侧闭孔淋巴结缩小了 50%。本病例表明，在这种情况下，曲美替尼具有治疗BRAF G469A突变的mBUC患者的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

摘要图片

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Efficacy of trametinib in a metastatic urothelial carcinoma patient with a BRAF mutation

Introduction

BRAF mutations in bladder cancer are rare. MEK inhibitors have excellent clinical benefits in the treatment of melanoma.

Case presentation

A 60-year-old male was diagnosed with muscle-invasive bladder cancer and underwent total cystectomy and ileal conduit diversion. Despite 4 cycles of gemcitabine and cisplatin chemotherapy and 3 courses of pembrolizumab, the left obturator lymph node enlarged. Cancer multi-gene panel testing confirmed the BRAF G469A mutation and trametinib was recommended. Three months after the initiation of trametinib (2 mg, qd), the left obturator lymph node shrank by more than 50%. The disease has remained stable for more than 18 months.